UCB (UCBJY) Stock Price, News & Analysis

Company Overview

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Key Stats

• Today's Range: $89.48 to $90.27
• 50-Day Range: $75.96 to $96.96
• 52-Week Range: $68.25 to $106.60
• Volume: 77,042 shs
• Average Volume: 48,489 shs
• Market Capitalization: $33.96 billion
• P/E Ratio: N/A
• Dividend Yield: 0.53%
• Price Target: N/A
• Consensus Rating: N/A

UCBJY Stock Analysis - Frequently Asked Questions

How have UCBJY shares performed this year?

UCB's stock was trading at $98.85 at the beginning of 2025. Since then, UCBJY shares have decreased by 9.1% and is now trading at $89.8375.
View the best growth stocks for 2025 here.

How do I buy shares of UCB?

Shares of UCBJY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Ex-Dividend for 5/14 Dividend: 4/28/2025
• Record date for 5/14 Dividend: 4/29/2025
• Dividend Payable: 5/14/2025
• Today: 5/28/2025
• Next Earnings (Estimated): 7/23/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:UCBJY
• Previous Symbol: OTCMKTS:UCBJY
• CIK: 1290640
• Web: www.ucb.com
• Phone: (322) 559-9999
• Fax: 32-2559-9900
• Employees: 9,083
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: 35.37
• P/E Growth: 0.69
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.33
• Current Ratio: 1.19
• Quick Ratio: 0.78

Sales & Book Value

• Annual Sales: $5.27 billion
• Price / Sales: 6.45
• Cash Flow: $3.76 per share
• Price / Cash Flow: 23.88
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 378,040,000
• Free Float: N/A
• Market Cap: $33.96 billion
• Optionable: Not Optionable
• Beta: 0.54